Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Amortization of Deferred Charges: 2012-2024

Historic Amortization of Deferred Charges for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $3.7 million.

  • Ocular Therapeutix's Amortization of Deferred Charges rose 22.06% to $758,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 26.17%. This contributed to the annual value of $3.7 million for FY2024, which is 38.85% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Amortization of Deferred Charges of $3.7 million as of FY2024, which was down 38.85% from $6.1 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Amortization of Deferred Charges ranged from a high of $6.1 million in FY2023 and a low of $3.7 million during FY2024.
  • In the last 3 years, Ocular Therapeutix's Amortization of Deferred Charges had a median value of $4.9 million in 2022 and averaged $4.9 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Amortization of Deferred Charges climbed by 25.82% in 2023, and later tumbled by 38.85% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Amortization of Deferred Charges (Yearly) stood at $4.4 million in 2020, then rose by 4.82% to $4.6 million in 2021, then grew by 4.86% to $4.9 million in 2022, then rose by 25.82% to $6.1 million in 2023, then plummeted by 38.85% to $3.7 million in 2024.